Corxel Pharmaceuticals
Privately held: no public share price · China / United States
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Cardiac myosin (activator)Small molecule | Heart Failure Heart Failure with Reduced Ejection Fraction |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
Est. primary completion 2027-09 · NCT06736574 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
28 February 2023Complete response letterOmecamtiv mecarbilFDA issues a complete response letter for the omecamtiv mecarbil NDA in HFrEF
US, FDA · Cytokinetics, Incorporated · Source ↗
Financial reports
No financial reports recorded.